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Introduction
Background: PFAPA syndrome is the most frequent
periodic fever syndrome in non-Mediterranean patients.
The cause remains obscure but overexpression of inflam-
masome-related genes and increase IL-1b during attacks
suggest an autoinflammatory mechanism. We wondered
whether colchicine could be used as effective prophylactic
treatment in PFAPA syndrome.
Objectives
To compare 2 groups of PFAPA patients distinguished by
their response to colchicine prophylaxis, and to identify
the predictive factors of response to this treatment.
Methods
We performed a retrospective, multicentric, chart review
of PFAPA patients under colchicine prophylaxis. We
distinguished one responder group, defined as patients,
who had no more, or twice fewer crises under colchicine
and another one of non-responders. Subgroup analyses
were performed using the nonparametric Mann-Whitney
test for the quantitative data and calculating the odds ratio
and confidence interval for qualitative data. The difference
between the two groups was considered significant for
p value <0.05 or a confidence interval different from 1.
Results
Twenty children, 65% of boys, were studied. Their mean
age at disease onset was 2.3 ± 1.5 years. The mean dura-
tion of attacks was 3.2 ± 1.1 days (SD) (1 to 7 days) of
strong fever (mean 39.9°C) with chills (30%), pharyngitis
(85%), abdominal pain (75%), cervical adenitis (65%), asth-
enia (60%) and aphtous stomatitis (50%). Half of patients,
57% (8/14) were heterozygous in the MEFV gene. Nine
patients were responders to colchicine. No significant
differences were found between the two groups (responder
and non-responder).
Conclusion
We observed a relatively high rate of response to colchi-
cine; however our study could not sort out the predictive
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